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Introduction
PDYN is the precursor protein for the opioid peptides -neoendorphin, dynorphin A, and dynorphin B. The actions of these neuropeptides are mediated via the kappa-opioid receptor (encoded by OPRK1) (Akil et al., 1984; Merg et al., 2006) . Dynorphins regulate pain, substance dependence, and stress-induced responses via opioidreceptor signalling (Hauser et al., 2005; Chavkin, 2013) . However, dynorphin A can also exhibit non-opioidmediated neurotoxic effects, as elevated peptide levels cause allodynia, paralysis and neuronal loss in the spinal cord of mice, which could not be blocked by an opioid antagonist (Herman et al., 1980; Walker et al., 1982; Hauser et al., 2005) . Dynorphin A was shown to cause pronounced cell death that was dependent on the presence of NMDA-Rs (N-methyl D-aspartate receptors) (Tan-No et al., 2001) . Additional neurotoxic mechanisms of dynorphins may be mediated via numerous receptors and/ or channels such as AMPA-Rs (-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors) (Singh et al., 2003) or ASIC1a (acid-sensing ion 1a) channels (Sherwood and Askwith, 2009 ).
Mutations in PDYN were shown to cause spinocerebellar ataxia type 23 (SCA23), a slowly progressive, autosomal dominant neurodegenerative disorder (Bakalkin et al., 2010) . SCA23 patients suffer from relatively slowly progressive impairment of their motor coordination, and a fairly pure cerebellar ataxia due to Purkinje cell death in the cerebellum (Verbeek et al., 2004) . The majority of SCA23 mutations located in the highly conserved dynorphin A-coding region lead to enhanced levels of mutant dynorphin A in cells, either due to higher peptide production or increased peptide stability (Bakalkin et al., 2010) . These mutant dynorphin A peptides displayed neurotoxic properties in cultured striatal neurons (Bakalkin et al., 2010) , and induce pathological pain when injected into mice in femtomolar doses (Watanabe et al., 2012) . Although the mechanism is unclear, recent studies indicate that these mutant peptides interact with and penetrate cellular membranes in vitro, and thus lead to cell death (Madani et al., 2011; Bjö rnerå s et al., 2013) . Increased expression of PDYN and its neuropeptides have also been implicated in age-related decline of cognition and memory (Kotz et al., 2004; Ménard et al., 2013) .
Furthermore, elevated dynorphin A levels have been linked to the pathology of Alzheimer's disease (Yakovleva et al., 2007) , supporting a crucial role for elevated opioid neuropeptides levels in the aetiology of neurodegenerative disorders.
To reveal the causality between mutations in PDYN and SCA23, we generated transgenic mice ubiquitously expressing wild-type PDYN (PDYN WT ) or SCA23-mutant PDYN-R212W (PDYN R212W ) and examined whether mutant dynorphin A may impair motor performance and induce neuropathological changes similar to those in patients with SCA23.
Materials and methods

Animals
All animal experiments were performed according to the guidelines of the University of Groningen, The Netherlands, and the Mayo Clinic College of Medicine, Rochester, Minnesota, USA. The experimental protocols were approved by the Animal Welfare Committee of the University of Groningen. All efforts were made to reduce the number of animals and minimize their suffering. To generate transgenic mice expressing wild-type (WT) PDYN or SCA23-mutant PDYN-R212W under Cre-recombinase control, the PDYN cDNA was cloned into the pCALL2 plasmid downstream of a neomycin-resistance gene and transcription stop signal (three tandemly arranged polyadenylation sites) flanked by loxP sites (van Ree et al., 2010) . Embryonic stem cell electroporation and clone selection was performed as described previously (van Ree et al., 2010; Baker et al., 2013) . The blastocyst injections were performed at the Mayo Clinic College of Medicine. The genotypes were assessed by PCR using the following primers: PDYN-For 5'-TAGCAGTGGCG TTCATTTTG-3' and PDYN-Rev 5'-TCTGAGCTCCTCTTGG GGTA-3'; loxP-For 5'-TCACTGCATTCTAGTTGTGGT-3', and loxP-Rev 5'-CTTATCGATACCGTCGACCT-3'.
All mice used for the experiments had a mixed 129Sv/ E Â C57Bl/6 genetic background, and wild-type littermates were used as controls. Four independent cohorts (n = 10-12) of PDYN WT and PDYN R212W , and littermate controls were aged for 3, 6, 9 and 12 months. Each cohort contained equal numbers of male and female mice, and the mice were of the indicated age. In addition to PDYN, transgenic mice also ubiquitously express enhanced green fluorescent protein (EGFP). 
Protein extraction and western blotting
Proteins were isolated from snap-frozen mouse organs. Organs were homogenized in ice-cold isolation buffer [1% Triton TM X-100 (Sigma) in 10 mM Tris-HEPES, pH7.6] supplemented with a complete protease inhibitor cocktail (Roche) and 50 mM dithiothreitol. Samples were centrifuged for 15 min at 10 000 rpm, and protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific), 2Â Novex Tricine SDS sample buffer (Life Technologies) was added to the protein lysates and equal amounts were loaded on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels. After electrophoresis, the proteins were transferred to polyvinylidene difluoride (PVDF) membrane (Life Technologies) and blocked with 5% non-fat milk in Tris-buffered saline (TBS)-Tween. The blots were analysed with primary antibodies against human PDYN (rabbit, 1:500), dynorphin A (rabbit, 1:300, Abcam), vesicular glutamate transporter 2 (vGlut2; rabbit, 1:1000, Synaptic Systems), EAAT4 (rabbit, 1:500, Alpha Diagnostics) or Calbindin (mouse, 1:500, Abcam). Secondary antibodies were conjugated with horseradish peroxidase (goat, 1:10 000, Jackson ImmunoResearch Laboratories). Densitometric analysis was performed using Fiji software (National Institutes of Health, USA, http://fiji.sc/). Protein bands were normalized against tubulin bands of the same sample.
Radioimmunoassay
The radioimmunoassay procedure was described elsewhere (Christensson-Nylander et al., 1985; Yakovleva et al., 2006) . Briefly, tissue samples were extracted in 1 M acetic acid, peptide fractions were isolated by SP Sephadex Õ ion exchange C-25 chromatography, and peptides were analysed by radioimmunoassay.
Histology, immunofluorescent stainings, silver stainings and microscopy For immunofluorescent stainings, brains were dissected and fixed overnight in 15% picric acid, 4% paraformaldehyde and 0.05% glutaraldehyde in 0.1 M phosphate buffer. After fixation, brains were cryopreserved in 10% and 20% sucrose solutions in phosphate buffer overnight, and then frozen on dry ice. Sectioning was performed on an HM550 Microm cryostat (Thermo Scientific). Cerebella were cut into eight series of 30-mm thick coronal sections. All stainings were performed free floating. For overall morphology studies, sections were stained with 1% Toluidine Blue (Sigma-Aldrich) for 2 min, washed with water, and mounted in Faramount mounting medium (Dako). For fluorescent staining, sections were blocked with 3% normal donkey serum (Jackson ImmunoResearch Laboratories) for 30 min, after which antigen retrieval was carried out in 10 mM citric acid buffer (pH 6.0) at 90 C for 20 min. Sections were washed in TBS, alternated with TBS with 1% Tween for permeabilization. Sections were incubated with primary antibody overnight at 4 C and subsequently with secondary antibodies for 1 h at room temperature, followed by Sudan Black B incubation to eliminate autofluorescence and transgenic GFP fluorescence (0.1% in 70% ethanol; Sigma-Aldrich) ( Supplementary Fig. 1A-F) , washing with phosphate buffer + 0.02% Tween, and mounting (BrightMount mounting medium). The primary antibodies used were: anti-human PDYN (rabbit, 1:300, Yakovleva et al., 2006) anti-dynorphin A (rabbit, 1:300, Abcam), anti-vGlut2 (rabbit, 1:1000, Synaptic Systems), anti-EAAT4 (rabbit, 1:500, Alpha Diagnostics) and anti-Calbindin (mouse, 1:500, Abcam). Secondary anti-rabbit antibodies were conjugated with Alexa Fluor Õ 488 and anti-mouse antibodies with Cy3 (both: donkey, 1:250, Jackson ImmunoResearch Laboratories).
For silver stainings, brain samples were dehydrated with a graded ethanol series, followed by xylene and paraffination. Paraffin sections were cut at a thickness of 5 mm. After subsequent deparaffination and rehydration, the cerebellar slides were placed in a 20% AgNO 3 solution for 20 min at 60 C. After rinsing in distilled water, the slides were placed in a solution of 10% AgNO 3 (to which ammonia was added until the precipitate was dissolved) + 1 ml of 25% sodium carbonate solution. The solution was stirred while drops of 3.7% formalin were added until the slides stained golden brown. After being rinsed in distilled water, the slides were placed in 5% sodium thiosulphate solution for 2 min. Then the slides were rinsed again, followed by dehydration, xylene, and mounting. These slides were evaluated for the formation of 'torpedoes' (indicating axonal damage of Purkinje cells) and 'empty baskets' (indicating complete loss of individual Purkinje cells).
Sections were imaged using an AxioObserver Z1 fluorescence microscope (Zeiss) and Leica TCS SP8 confocal microscope, and the images were analysed using the ImageScope (Aperio e-pathology solutions, http://www.aperio.com) and Fiji software (National Institutes of Health, http://fiji.sc/).
Motor performance analyses
Footprint patterns were analysed using a runway (80 cm Â 10.5 cm wide) with white paper on the bottom. Mouse paws were painted with non-toxic, water-soluble ink (black for hind paws and magenta for front paws; Liquitex). Five consecutive strides were measured for each animal (Brooks and Dunnett, 2009 ). To assess motor performance the accelerating rotarod test was used (3-cm diameter rotating cylinder; IITC). The training session contained three runs at a stable 20 rpm at Day 1, followed by two training days (three runs per day) at accelerating speed (from 4 to 30 rpm within 180 s, running 600 s in total). The experiment was performed on Day 4, identical to the exercise on Days 2 and 3. The minimal interval time in between the runs was 15 min (Brooks and Dunnett, 2009 ). All tests were performed without genotype information and scored and analysed by two independent researchers.
Cerebellar examinations: Purkinje cell count, molecular layer thickness and climbing fibre distribution Purkinje cells were counted and averaged over 100 mm and the climbing fibre distribution was quantified by measuring the height of the vGlut2 staining in the molecular layer relative to the calbindin staining in the same region. The Purkinje cell length was measured as the distance from the top of Purkinje cell soma to the tip of Purkinje cell dendrite, and the climbing fibre distribution in the molecular layer was measured from the top of Purkinje cell soma to the tip of climbing fibre arbour. In addition, the molecular layer thickness was measured. For molecular layer thickness and climbing fibre distribution, at least 10 measurements per section were taken in specific cerebellar regions. One series of cerebellar sections per animal and two animals per genotype (controls, PDYN WT and PDYN R212W ) were used for one staining. Full cerebellar regions including cerebellar lobules II, III, IV/V, VI, IX and X, the paramedian lobule, paraflocculus, flocculus and simplex and CrusI and CrusII ansiform lobules (Sim/Crus) were present in different sections and two to five sections were analysed per region.
Cerebellar primary cultures
Cerebella of postnatal Day 5 pups were dissected and were kept on ice in supplemented PBS (0.3% bovine serum albumin and 0.6% glucose) after removal of the meninges. After trypsinization, cerebella were disaggregated in Dulbecco's modified Eagle medium supplemented with 10% foetal bovine serum (FBS), 0.25% penicillin/streptomycin and DNase I (Sigma-Aldrich), with a succession of pipettes, decreasing in size. Cells were then counted and $200 000 cells were seeded onto poly-D-lysine/laminin coated glass coverslips in 24-wells plates, in Neurobasal Õ medium (Life Technologies, Gibco), supplemented with 0.5% FBS, 0.25% glutamine, 0.25% penicillin/streptomycin, and B27 (Life Technologies, Gibco). After 24 h of culturing, inhibitor Ara-C (Sigma-Aldrich) was added to the culture medium to decrease glial cell growth. Neurons were cultured for 10 days before experiments were conducted.
Immunocytochemistry
Cerebellar neurons were fixed in 4% paraformaldehyde for 10 min and washed with PBS. Blocking and permeabilization was performed with 5% normal donkey serum (Jackson ImmunoResearch Laboratories) and 0.1% Triton (Sigma-Aldrich) in PBS for 1 h. Neurons were incubated with primary antibodies overnight at 4 C, and for 1 h with secondary antibodies at room temperature. All antibodies were diluted in blocking solution, and the primary antibodies used were anti-human PDYN (rabbit, 1:100; Yakovleva et al., 2006) , anti-dynorphin A (rabbit, 1:100, Abcam) and anti-b3 tubulin (mouse, 1:100, Santa Cruz Biotechnology). Secondary anti-rabbit antibodies were conjugated with Alexa Fluor Õ 488 and anti-mouse antibodies with Cy3 (both: donkey, 1:250, Jackson ImmunoResearch Laboratories).
Neurons were imaged using a Leica TCS SP8 confocal microscope, and the images were analysed using Fiji software (National Institutes of Health, http://fiji.sc/).
Electrophysiological recordings
The cerebellar neurons cultured on the poly-D-lysine/laminincoated coverslips were placed in a measuring chamber attached to an Axioskop 2 FS microscope (Zeiss). Membrane currents and voltages were measured using an Axopatch 200 B amplifier (Axon Instruments), using the whole-cell patch clamp technique. Pipettes were pulled from borosilicate glass (Clarke) and were filled with a solution containing: KCl 140 mM, HEPES 10 mM, EGTA 10 mM, MgCl 2 1 mM, CaCl 2 1 mM, Na 2 ATP 2 mM (280-290 mOsm). The bathing solution contained NaCl 140 mM, KCl 4 mM, glucose 10 mM, CaCl 2 2 mM, HEPES 1.2 mM and MgCl 2 1 mM (mOsm 330). The pH of all solutions was adjusted to 7.40. When used with these solutions, the pipettes had initial resistances of 5-8 M. Membrane currents were recorded at room temperature (20) (21) (22) C) with the amplifier in voltage clamp mode.
Currents were low-pass filtered at 5 kHz and sampled at 50 kHz using a Digidata 1320 AD converter (Axon Instruments). Pipette capacitance and whole cell resistance were compensated by 80-85%. After measuring the membrane currents, the amplifier was switched to current clamp mode. Following measurement of the resting membrane potential, the membrane potential was set to À50 mV using steady injected current through the patch pipette. Input resistance was measured using small depolarizing current steps. The cell was activated with a 500 ms pulse of depolarizing current. Voltage clamp step protocols were generated and data was analysed using Pclamp software (Axon Instruments).
Statistical analysis
All data was normalized against 3-month control data and expressed as mean AE standard error of the mean (SEM), unless stated otherwise. Two-way ANOVA was used to determine the significance of the observed differences between the genotypes, and over time, unless stated otherwise (P 5 0.05 is considered statistically significant).
Results
Expression of SCA23-mutant PDYN-R212W leads to elevated levels of cerebellar mutant dynorphin A Previous studies have shown that the SCA23 mutation, R212W, has the strongest effects on dynorphin A levels in cell models compared to other mutations (Bakalkin et al., 2010) . In addition, R212W induces the strongest non-opioid nociceptive activity upon injection of dynorphin A into mice (Watanabe et al., 2012) . To examine the causal role of mutant PDYN-R212W in the pathology of SCA23, we ubiquitously expressed PDYN-wt or PDYN-R212W by crossing (PDYN   WT   ) flox/flox and (PDYN R212W ) flox/flox mice with hypoxanthine-guanine phosphoribosyl transferaseCre (HPRT-Cre) mice (Nichol et al., 2011) (Fig. 1A) .
Heterozygous PDYN WT and PDYN R212W mice were born at the expected Mendelian frequency, were fertile, appeared healthy, and displayed body weight that was indistinguishable from control littermates (data not shown). Transgenic PDYN mRNA expression was equally high in the cerebella of PDYN WT and PDYN R212W mice at 3 months of age ( Fig.  1B) , which significantly decreased in PDYN WT mice but not in PDYN R212W mice at 12 months of age (Supplementary Fig. 2A ). Transgenic PDYN wild-type or R212W expression did not affect endogenous Pdyn mRNA expression at 3 months of age (Fig. 1C) , whereas clearly reduced Pdyn expression was observed in PDYN R212W mice at 12 months of age ( Supplementary Fig. 2B ). This led to approximately equal PDYN/Pdyn mRNA levels in both models at 3 and 12 months of age. Both PDYN WT and PDYN R212W mice Figs 2C-H and 4) . These results suggest that PDYN-R212W is either more efficiently processed into peptides or is more rapidly degraded than PDYN-wt.
To examine the processing of PDYN-wt and PDYN-R212W to dynorphin A, dynorphin B and conversion to Arg-Leu-enkephalin (Leu-ENK-Arg 6 ), the cerebella of PDYN WT , PDYN R212W mice and their age-matched controls were analysed by radioimmunoassay. We observed that PDYN expression resulted in marked increased levels of dynorphin A and dynorphin B in the cerebella of PDYN WT and PDYN R212W mice, compared to littermate controls at 3 and 12 months of age ( Fig. 1G and Supplementary Fig. 2K ). Especially, significantly increased dynorphin A levels in PDYN R212W mice were observed compared to PDYN WT mice at both 3 and 12 months of age. This effect was not observed for dynorphin B and Leu-ENKArg 6 peptide levels, suggesting that the R212W mutation selectively alters the processing of PDYN to dynorphin A.
Consistent with clear cerebellar PDYN protein expression on western blot, strong and specific PDYN and dynorphin A immunofluorescence signals (in purple) were detected in the molecular, Purkinje cell and granule cell layers of PDYN WT and PDYN R212W mice at both age 3 and 12 months ( Fig. 2 and Supplementary Fig. 3 ). These signals were also observed in the Purkinje cell soma as was shown by co-localization with the Purkinje cell-specific marker calbindin (in green), indicating that Purkinje cells express PDYN and dynorphin A. In general, dynorphin A localized more to the molecular layer ( Fig. 2Q and R) than PDYN, which showed a more focal localization in the Purkinje cell soma ( Fig. 2H and I) .
Taken together, these results show that both transgenic mouse lines have robust expression of PDYN-wt or PDYN-R212W in the cerebellum. Despite the low precursor levels, PDYN R212W mice showed highly elevated ($2-3-fold) cerebellar mutant dynorphin A levels compared to PDYN WT mice. These results are in line with our previous data that showed that the PDYN R212W mutation led to significantly enhanced dynorphin A peptide levels in cell models (Bakalkin et al., 2010) , which is likely to be a direct consequence of enhanced PDYN-R212W processing.
Expression of PDYN-R212W causes Purkinje cell death and loss of climbing fibre-Purkinje cell innervation
To investigate whether PDYN-wt or PDYN-R212W expression causes cerebellar pathology, we performed a toluidine blue staining to study the gross morphology of the cerebellum. The cerebella of both PDYN WT and PDYN R212W mice did not show any major abnormalities and were of similar size as littermate controls at 3 and 12 months of age, including the molecular layer (Supplementary Fig. 4A-G) . However, lobule II did show significant thinning in 12-month-old PDYN R212W mice (Supplementary Fig. 4G ) and a more detailed analysis revealed significantly marked Purkinje cell loss in the vermal lobules II, III, VI and in the hemispheric regions Sim/Crus of 12-month-old PDYN R12W mice compared to both PDYN WT mice and littermate controls (Fig. 3A) . This was not observed at 3 months of age (data not shown). The age-dependent Purkinje cell pathology was confirmed by calbindin immunostainings and Sevier-Munger stainings. Purkinje cells of 12-month-old PDYN R212W mice showed mild atrophy of the dendritic tree and loss of Calbindin staining (Fig. 3B-D) . Additionally, Sevier-Munger stainings demonstrated several stages of Purkinje cell damage in PDYN R212W mice, including rare axonal torpedoes (Fig. 3E ), single and multiple empty baskets ( Fig. 3F and G), and chronic Purkinje cell loss indicated by the absence of normal Purkinje cell layer structure (Purkinje cells and basket cells) (Fig. 3H) . In contrast, age-matched PDYN WT and littermate control cerebella only very rarely displayed a single empty basket, which was most likely the result of normal ageing (data not shown). Larger stretches with empty baskets or areas with chronic Purkinje cell loss were never observed. No Purkinje cell layer pathology was observed in 3-month-old PDYN R212W mice (data not shown), suggesting degeneration occurs relatively late and progresses slowly, mirroring the human disease (Verbeek et al., 2004) .
Next, we analysed the Purkinje cell pathology more precisely by examining climbing fibre-Purkinje cell synapses, using vGlut2 as a marker (Fremeau et al., 2001) . Altered distribution of climbing fibre synapses was previously seen in SCA1 and SCA7 mice (Duvick et al., 2010; Furrer et al., 2013) , reflected by reduced vGlut2/calbindin ratios along the Purkinje cell dendrites. The Purkinje cell dendrites of PDYN R212W mice showed a significantly reduced climbing fibre synapse distribution in the vermal lobules II, VI and IX, and in the paraflocculus compared to PDYN R212W mice and littermate controls, respectively ( Fig. 4A and B) . These effects were also observed in lobules II, VI, IX, and paraflocculus of 3-month-old PDYN R212W mice which significantly progressed over time up to 12 months of age (Fig. 4B) . This suggests that expression of PDYN-R212W caused early changes in the climbing fibre-Purkinje cell synapses, and that these changes progress with age and lead to Purkinje cell degeneration over time. Notably, the loss of climbing fibre-Purkinje cell synapses is mostly restricted to the anterior vermis and lobule VI; regions found to be responsible for motor coordination and balance (Manni and Petrosini, 2004; Stoodley and Schmahmann, 2010) . To test whether the subtle but significant and progressive morphological alterations observed above translate into neurological effects, we assessed gait-and motor performance over time using footprint pattern analysis and the accelerating rod test. Footprint patterns were analysed for differences in hind base width and the overlap of steps between the front and hind paws, which are characteristic for ataxia (Manto and Marmolino, 2009 ). The hind base width of PDYN R212W mice was significantly wider than PDYN WT mice at all ages, and significantly wider than control mice at 3, 6 and 9 months of age (Fig. 5A ). Already at 3 months of age, PDYN R212W mice also showed significant loss of step overlap in contrast to PDYN WT and control mice, which progressively reached maximal loss of step overlap at 9-12 months of age (Fig.  5B) . The performance on the accelerating rod was only significantly diminished in PDYN R212W mice at 12 months of age compared to littermate controls, as their time on the rod was markedly reduced (Fig. 5C) . Although 12-month-old PDYN R212W mice performed worse than age-matched PDYN WT mice, this difference was not significant.
Altogether, these data show that PDYN R212W mice exhibit a mild, slowly progressive, impairment of motor coordination with deficits in balance and step alterations, reflecting the mild and progressive neurological symptoms of SCA23 patients.
PDYN
R212W mice show altered expression of opioid and glutamatergic signalling
To address the consequence of the elevated mutant dynorphin A peptide levels on opioid signalling, we studied the mRNA expression levels of the opioid receptors Oprd1, Oprk1, and Oprm1. The expression of PDYN-wt and PDYN-R212W did not affect Oprd1, Oprk1 and Oprm1 mRNA levels in cerebellum at 3 months of age (Fig. 6A ), but at 12 months of age, PDYN WT mice and control mice showed significantly increased Oprk1 and Oprm1 mRNA expression levels compared to PDYN R212W mice (Fig. 6A) . Notably, this increase in receptor expression was also significant over time for the control mice but not for PDYN WT mice. Thus, PDYN-R212W reduced opioid receptor expression in the cerebellum at 12 months of age.
We hypothesized that the abundant mutant dynorphin A peptides switch to another receptor system as has been described for elevated wild type dynorphin A levels in a pain model (Lai et al., 2006) . Therefore, we next studied the mRNA expression levels of components of the glutamatergic system over time in cerebellum, including the NMDA-R subunits Grin1, Grin2a, and Grin2b, the AMPA-R subunits Gria2 and Gria3, as dynorphin A-induced cell death in cell models was previously shown to be mediated via both NMDA-Rs (Tan-No et al., 2001) and AMPA-Rs (Singh et al., 2003) . No significant differences were detected for Grin1 and Grin2b mRNA levels between the different genotypes and time points. However, a significant increase in Grin2a expression was observed in 3-month-old PDYN R212W mice compared to PDYN WT and littermate controls, but not at 12 months of age (Fig. 6B ). Gria2 and Gria3 mRNA levels were identical for all genotypes at age 3 months, but the trend in age-dependent decline (not significant) in Gria2 and Gria3 expression in controls and PDYN WT mice was significantly prevented in PDYN R212W mice (Fig. 6C) . We lastly examined the expression of glutamate transporters Slc1a3, Slc1a1 and Slc1a6. At 3 months, only Slc1a1 mRNA levels were significantly elevated in PDYN R212W mice compared to control mice (Fig. 6D) . Whereas a significant increase in Slc1a3 expression was seen in 12-monthold PDYN R212W mice compared to PDYN WT mice and littermate controls (Fig. 6D) . These changes in the mRNA levels of components of the glutamatergic system imply that expression of PDYN-R212W affects the glutamate system.
Overall, these results indicate that the elevated mutant dynorphin A levels likely add to disturbed opioid and glutamatergic signalling in the cerebellum and subsequently contributes to SCA pathogenesis.
Increased expression of PDYN-R212W causes electrophysiological changes in cultured cerebellar neurons
To determine whether expression of PDYN-R212W causes altered neuronal excitability in the cerebellum, we performed electrophysiological experiments on cultured cerebellar neurons from P5 control, PDYN WT and PDYN
R212W
pups. As shown in Supplementary Fig. 7 , PDYN WT and PDYN R212W cultures expressed PDYN at similar levels ( Supplementary Fig. 7E-L) , whereas control cultures only showed background staining ( Supplementary Fig. 7A-D) . All cultures expressed dynorphin A, with the lowest levels in control neurons and the highest levels in PDYN R212W neurons ( Supplementary Fig. 7M-X) , similar to mice at 3 and 12 months of age. No significant morphological differences were observed between the genotypes (data not shown). The cultured neurons were analysed at 10 days in vitro by whole cell patching, and whole cell currents were compared. We showed that PDYN R212W cerebellar neurons exhibit similar expression of voltage-dependent membrane currents (IV curve) compared to PDYN WT cerebellar neurons (Fig. 7A) . Additionally, both PDYN WT and PDYN R212W cerebellar neurons showed significantly smaller Na + and K + currents than cerebellar neurons from control littermates. This suggests that overexpression of PDYN already has an effect on the physiological functioning of the cell.
Current clamp recordings showed that control cerebellar neurons were characterized by fast spike action potentials with an amplitude of 61.8 AE 3.1 mV and a half-width of 2.6 AE 0.3 ms (Fig. 7B) . PDYN WT neurons displayed typical granule cell action potentials (Huang et al., 1993) with a fast spike amplitude of 66.9 AE 3.1 mV and a half-width of 2 AE 0.1 ms (Fig. 7C) . The activity in PDYN R212W cerebellar neurons was different from the other genotypes, in that the amplitude of the spikelets was much smaller, 37.2 AE 2.4 mV (Fig. 7D) , and the membrane did not reach 0 mV. Furthermore, these spikelets had a half-width of 9.7 AE 1.1 ms (Fig. 7D) . Additionally, PDYN R212W cerebellar neurons displayed another action potential waveform, which can be described as a small excitatory post synaptic potential that did not progress into an action potential (Fig.  7E) . Taken together, these results suggest that increased expression of PDYN impairs cell functioning leading to reduced Na + and K + currents. Furthermore, expression of PDYN-R212W causes a significant change in the action potential waveform of cultured PDYN R212W cerebellar neurons affecting neuronal excitability.
Discussion
In this study, we generated the first mouse model for SCA23 and shown that mice expressing PDYN-R212W recapitulate many characteristics of the human phenotype of SCA23 (Verbeek et al., 2004) . PDYN R212W mice develop mild, slowly progressing ataxia, with subtle gait abnormalities detected at 3 months of age, and an overall decline in motor performance at 12 months of age, related to synaptic alterations in Purkinje cells (early) and Purkinje cell loss (later), coinciding with elevated mutant dynorphin A peptide levels. The loss of climbing fibre-Purkinje cell synapses most likely contributes to the early motor deficits in PDYN R212W mice, by causing Purkinje cell malfunctioning and eventually cell death. The observation that the climbing fibre retraction is progressive, suggests that loss of climbing fibre-Purkinje cell synapses is caused by active elimination, rather than by a developmental issue (Ebner et al., 2013) . Additionally, loss of climbing fibre-Purkinje cell synapses seems to be common in SCA pathology including SCA1, SCA7 and SCA14 (Duvick et al., 2010; Shuvaev et al., 2011; Furrer et al., 2013) . However, the relative mild pathology of the PDYN R212W mice correlates more with the conventional (non-polyglutamine) SCA5 mouse model, which displayed Purkinje cell loss from 6 months of age (Perkins et al., 2010) . The region most affected by neurodegeneration was the anterior vermis, a region known to be involved in motor coordination and balance (Manni and Petrosini, 2004; Stoodley and Schmahmann, 2010) , again mimicking the human disease (Verbeek et al., 2004) . The question remains why PDYN R212W mice show relatively restricted cerebellar pathology. We hypothesize that mutant dynorphin A is mimicking the actions of glutamate, and selectively targets NMDA receptors comprised of NR2A and NR2B subunits instead of its native opioid receptors. These NMDA receptors mainly mediate excita- WT and PDYN R212W mice at 3, 6, 9 and 12 months of age (n = 6, per transgenic line and n = 12 for controls). PDYN R212W mice showed a significantly wider hind limb base (3.67 AE 0.11) than PDYN WT (2.67 AE 0.04) and control mice (3.35 AE 0.07) at 3 months of age. This effect persisted up to 12 months of age, where PDYN R212W mice showed a hind limb base with of 2.77 AE 0.08 compared to 2.33 AE 0.05 and 2.66 AE 0.05 in age-matched PDYN WT and control mice, respectively. Students t-test, *P 5 0.05, and ***P 5 0.001, ****P 5 0.0001, and *****P 5 0.00001. (B) Foot print pattern analysis of the overlap of front and hind paw footprints in control, PDYN WT and PDYN R212W mice at 3, 6, 9, and 12 months of age (n = 6, per transgenic line and n = 12 for controls). Perfect step overlap equals a score of 0. Significant loss of step overlap in PDYN R212W mice (0.33 AE 0.1) was observed starting at 3 months of age compared to PDYN WT (À0.11 AE 0.06) and control mice (0 AE 0.06). This deficit progressed with aging up to 9 months of age (range 0.33-1.15 AE 0.10). Loss of step overlap was not observed in PDYN WT mice or littermate controls. One-way ANOVA, **P 5 0.01, and ***P 5 0.001 (C) Quantification of the latency to fall from the accelerating rotarod performance on experimental Day 4 of control, PDYN WT and PDYN R212W mice at 3, 6, 9, and 12 months of age (n = 6, per transgenic line and n = 12 for controls). Only at 12 months of age PDYN R212W mice showed a significantly decreased latency to fall compared with similarly aged (Renzi et al., 2007) , and overactivation may contribute to retraction of climbing fibres, affecting intracellular calcium concentrations and induction of cerebellar plasticity which plays an important role in preserving motor performance (Hansel et al., 2001; Cerminara and Rawson, 2004; Hirano, 2013) . This work confirms our previous genetic and cellular findings (Bakalkin et al., 2010) , and shows that the R212W mutation in PDYN results in elevated dynorphin A levels in vivo and causes cerebellar ataxia. The elevated dynorphin A peptide levels are probably the result of enhanced PDYN-R212W processing, as low precursor protein levels were detected in PDYN R212W mice. Additionally, the R212W mutation may stabilize the mutant peptide, as unchanged levels of the peptide cleavage product, Leu-ENK-Arg 6 , were observed. This suggests that mutant dynorphin A is degraded less efficiently, leading to accumulation of mutant dynorphin A, but not dynorphin B, in the tissue. Additionally, the elevated levels of mutant dynorphin A are very likely the cause of Purkinje cell death and cerebellar ataxia.
Previous studies have already shown that dynorphin A can cause cytotoxicity through various non-opioid mechanisms (Hauser et al., 1999; Tan-No et al., 2001; Singh et al., 2002 Singh et al., , 2003 Sherwood and Askwith, 2009 ). Here, the Quantification of RT-PCR data of 3-and 12-month old cerebella of control, PDYN WT and PDYN R212W mice (n = 6, per genotype). All data were normalized to 3-month-old controls. (A) At 3 months of age, no significant difference was observed between the expression of the opioid receptors between the three genotypes. At 12 months of age, both PDYN WT and control mice showed significantly increased ($2.5-fold each)
Oprk1 and Oprm1 mRNA expression compared to PDYN R212W mice. This increase in receptor mRNA expression over time was only significant (Oprk1, P 5 0.0001 and Oprm1, P 5 0.0002) for control mice and not for PDYN WT mice. *P 5 0.05, **P 5 0.01 and ***P 5 0.001. (B) Grin2a mRNA expression was only significantly increased by $1.7-and $1.6-fold in 3-month-old PDYN R212W mice compared to PDYN WT and control mice, respectively. This was effect was no longer observed at 12 months of age. No significantly differences were detected in the mRNA expression of Grin1 and Grin2b between the genotypes or over time. **P 5 0.01 and ****P 5 0.0001. (C) No significant changes in Gria2 and Gria3 mRNA expression were detected between the various genotypes at 3 months of age. At 12 months, both Gria2 and Gria3 mRNA expression was significantly increased (Gria2, $1.3-fold and Gria3, $1.4-fold) in PDYN R212W mice compared to PDYN WT and control mice, respectively. However, this difference in mRNA expression levels was due to a decline in Gria2 and Gria3 mRNA expression in PDYN WT and control mice. *P 5 0.05 and increased mRNA levels of the NMDA-R subunit Grin2a, which is the major contributor of NMDA-R-mediated excitotoxicity (Engelhardt et al., 2006) , in PDYN R212W mice at 3 months of age make it tantalizing to speculate that mutant dynorphin A is (over)stimulating NMDA-Rs containing this subunit. Notably, dynorphin A was previously shown to directly interact with the NMDA-R and potentiates its glutamate currents (Woods et al., 2006) . The temporal decrease in mRNA expression of the Grin2a subunit may be a compensatory mechanism of the cells trying to decrease the NMDA-R-induced excitatory post synaptic potentials that may be caused by the elevated Grin2a mRNA levels (Renzi et al., 2007) . Additionally, PDYN R212W mice highly express glutamate transporters and AMPA-R subunits at 12 months of age. Increases in glutamate transporters may suggest that Purkinje cells and Bergmann glia perceive a high concentration of extracellular glutamate and attempt to clear this from the synaptic cleft. The changes in the mRNA expression of AMPA-R subunits may disturb the induction of cerebellar plasticity (Miyazaki et al., 2010) . Additionally, AMPA-R-mediated excitotoxicity was proposed as the underlying mechanism of Purkinje cell loss in SCA5 (Perkins et al., 2010) .
Another possible mechanism may be increased opioidmediated glutamate release, where mutant dynorphin A interacts with presynaptically located kappa-opioid receptor to induce release of glutamate, thereby indirectly activating NMDA-Rs (Kuzmin et al., 2013) . However, given the reduced mRNA expression of Oprk1 in PDYN R212W mice at 12 months of age, and the reduced affinity of mutant dynorphin A to bind to kappa-opioid receptor (unpublished data), this mechanism seems unlikely.
In addition, evidence is accumulating that dynorphin Amediated neurotoxicity may be non-receptor-mediated, as dynorphin A peptides were shown to interact with membranes, induce membrane leakage, and translocate across the plasma membrane, which could underlie neuronal cell death (Marinova et al., 2005; Madani et al., 2011; Bjö rnerå s et al., 2013) . Interestingly, similar mechanisms have been reported for the cytotoxicity of amyloid-b in Alzheimer's disease, where amyloid-b peptides were shown to activate extrasynaptic NMDA-Rs indirectly, leading to synaptic loss and/or changes in the permeability of membranes after inducing pore formations leading to increased amyloid formation and toxicity in vivo (Lashuel et al., 2003; Sepulveda et al., 2010; Nagarathinam et al., 2013; Talantova et al., 2013) .
The altered neuronal excitability as indicated by the distinct change in the amplitude and action potential waveform in cultured cerebellar neurons of PDYN R212W mice compared to PDYN WT and control cerebellar neurons likely indicate that expression of PDYN-R212W affects synaptic transmission. The spikelets cause little depolarization of the membrane, exhibit slow extinction affecting repolarization, and do not show overshoot fast spikes like PDYN WT and control neurons, showing resemblance to an immature phenotype of granule cells (Prestori et al., 2008) . As the cerebellar neurons examined here demonstrated action potential waveforms attributed to different cell populations including granule cells (Huang et al., 1993) , the relevance of these results with regard to Purkinje cell functioning need to be further investigated. This data complements our hypothesis of that expression of PDYN-R212W may cause altered synaptic efficiency, as information transfer at synapses is based upon changes in membrane polarization. Additionally, this finding could support the idea that mutant dynorphin A induces membrane leakage by interacting with the membrane and induces pores in the membrane (Marinova et al., 2005; Madani et al., 2011; Bjö rnerå s et al., 2013) , thereby changing the membrane potential and impeding expression of action potentials.
In conclusion, the PDYN R212W mouse is the first mouse model for SCA23, and it recapitulates the symptoms and cerebellar pathology of patients with SCA23. We show that the elevated mutant dynorphin A peptide levels are very likely responsible for the initiation and progression of SCA23 disease, and cause alterations in climbing fibrePurkinje cell synapse function and motor performance. Although the mechanism by which mutant dynorphin A causes neurotoxicity is not completely revealed, our results show that high levels of mutant dynorphin A correlate with increased expression of glutamate receptors, including NMDA-R and AMPA-R subunits that may cause intracellular calcium levels to increase, leading to transcriptional dysregulation and conceivably neurotoxicity (Fig. 8) . However, given the electrophysiological data, non-receptor mediated neurotoxicity could also underlie the pathology of SCA23.
Nevertheless, our mouse model provides unique opportunities to study the disease progression of a pure, isolated spinocerebellar ataxia during chronological ageing in more detail, because mutant mice develop their symptoms slowly. Moreover, our model may be of value beyond understanding SCA23 only, as elevated dynorphin A levels have also been linked to the pathology of Alzheimer's disease (Yakovleva et al., 2007) , supporting a more general implication of elevated opioid neuropeptides levels in the aetiology of neurodegenerative disorders.
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